# A Safety, Tolerability, and Efficacy Study of IBI314 in Ambulatory Patients With COVID-19

> **NCT05162365** · PHASE1,PHASE2 · TERMINATED · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 248 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** IBI314
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05162365
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-01-06
- **Primary completion:** 2022-06-29
- **Final completion:** 2022-11-18
- **Target enrollment:** 248 (ACTUAL)
- **Why stopped:** The company decision that terminated the further develop of the molecule and had notified FDA about the termination as well.
- **Last updated:** 2023-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05162365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05162365, "A Safety, Tolerability, and Efficacy Study of IBI314 in Ambulatory Patients With COVID-19". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05162365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*